A Phase 3 randomised study to evaluate the safety and antiviral activity of Remdesivir (GS-5734™) in participants with severe COVID-19 compared to standard of care treatment
Site and study lead:
- Oxford Road Campus – Dr Shazaad Ahmed
- Wythenshawe Hospital – Dr Tim Felton
- Royal Manchester Children’s Hospital – Dr Claire Murray
Patient group: COVID-19 patients in ICU
Funder: Gilead Sciences Inc.
Sponsor: Gilead Sciences Inc.
More about the GS-5773 study
- GS-5773 is a nationally-prioritised COVID-19 study. See the full list Urgent Public Health COVID-19 Studies on the NIHR website.
The primary purpose of this study is to evaluate the efficacy of two remdesivir (RDV) regimens with respect to the normalisation of temperature and oxygen saturation through Day 14 in participants with severe coronavirus disease (COVID-19).